Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GDC-0084 with Radiation Therapy for Brain or Leptomeningeal Metastases
NCT04192981Phase 1Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Dec 2019
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of paxalisib in brain metastasis (BM) and leptomeningeal metastasis (LM), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Maximum Tolerated Dose at 1 year. Started Dec 2019; status: active, not recruiting.
02
Drugs
paxalisib
03
Conditions
brain metastasis (BM)leptomeningeal metastasis (LM)
Beyond the preview
Go deeper on NCT04192981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04192981.